Abstract
Neuroendocrine neoplasias (NEN) comprise heterogeneous epithelial neoplasms with a large variety of clinical presentations, treatment options and outcomes. Since potentially all NEN bear malignant potential it is important for long-term clinical management and improvement of outcome to decide on successful and oncologically and economically meaningful follow-up strategies. Evidence-based outcome data validating specific follow-up strategies are, however, not available to date and thus outcome data, known prognostic factors and clinical experience guide the decisions on follow-up regimens. The review summarizes general recommendations as well as specific considerations based on tumor entities, clinicopathological tumor characteristics and clinical experience. Follow-up shall serve the patient to improve outcome, benefit from more effective therapies and suffer less from unnecessary and/or toxic therapeutic interventions and finally preserve or gain a good quality of life.
Original language | English |
---|---|
Pages (from-to) | 129-140 |
Number of pages | 12 |
Journal | Best Practice and Research: Clinical Endocrinology and Metabolism |
Volume | 30 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2016 |
Keywords
- follow-up
- grading
- neuroendocrine neoplasia
- outcome
- primary tumor
- prognosis
- quality of life
- staging